Comparison of Clinical Outcomes and Biochemical Markers in Normal and Preeclamptic Pregnancies: a Prospective Cohort Study

Overview

Journal Proc (Bayl Univ Med Cent)

Specialty General Medicine

Date 2023 Aug 24

PMID 37614853

Authors

Niraj Vora

Ram R Kalagiri

Kushi Shetty

Yara Mustafa

Waverly Kundysek

Muppala Raju

Vinayak Govande

Madhava Beeram

Mohammad Nasir Uddin

Affiliations

Soon will be listed here.

Abstract

Background: Preeclampsia (PreE), the de novo onset of hypertension and proteinuria at 20 weeks of gestation, is a leading cause of maternal and fetal morbidity and mortality. This study compared inflammatory biomarkers in PreE and normal pregnancies using paired samples of mothers and neonates.

Methods: Twenty normal pregnant and 27 PreE patients were monitored for biomarkers, neonatal outcomes, and placental morphologies. Fetal and maternal serum levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF), soluble endoglin (sENG), and soluble fms-like tyrosine kinase-1 (sFLT-1) were measured by enzyme-linked immunosorbent assay.

Results: Placental thickness was 25 mm in early PreE subjects compared to 32 mm in late PreE subjects ( < 0.05). Placental volume was 296 cm in early PreE compared to 393 cm in late PreE ( < 0.05). The average hospital stay for PreE babies was longer (20 ± 5 days) compared to babies from normal pregnancies (2 ± 1 days; < 0.05). PreE babies had a lower Ponderal index (2.28 ± 0.3) than those from normal pregnancies (2.95 ± 0.2; < 0.05). sENG and sFLT-1 had cord values like the maternal values, while VEGF and PlGF did not.

Conclusion: PreE alters the intrauterine environment by activating chemical mediators that result in maternal and fetal complications.

References

Shibata E, Rajakumar A, Powers R, Larkin R, Gilmour C, Bodnar L . Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005; 90(8):4895-903. DOI: 10.1210/jc.2004-1955. View

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

Jayet P, Rimoldi S, Stuber T, Salmon C, Hutter D, Rexhaj E . Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation. 2010; 122(5):488-94. DOI: 10.1161/CIRCULATIONAHA.110.941203. View

Nagamatsu T, Fujii T, Kusumi M, Zou L, Yamashita T, Osuga Y . Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology. 2004; 145(11):4838-45. DOI: 10.1210/en.2004-0533. View

Maharaj A, Walshe T, Saint-Geniez M, Venkatesha S, Maldonado A, Himes N . VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med. 2008; 205(2):491-501. PMC: 2271023. DOI: 10.1084/jem.20072041. View

Soto E, Romero R, Kusanovic J, Ogge G, Hussein Y, Yeo L . Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med. 2011; 25(5):498-507. PMC: 3401571. DOI: 10.3109/14767058.2011.591461. View

Lin S, Leonard D, Co M, Mukhopadhyay D, Giri B, Perger L . Pre-eclampsia has an adverse impact on maternal and fetal health. Transl Res. 2014; 165(4):449-63. DOI: 10.1016/j.trsl.2014.10.006. View

Levine R, Karumanchi S . Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005; 48(2):372-86. DOI: 10.1097/01.grf.0000160313.82606.d7. View

Buhimschi C, Norwitz E, Funai E, Richman S, Guller S, Lockwood C . Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005; 192(3):734-41. DOI: 10.1016/j.ajog.2004.12.052. View

10.

Sibai B, Dekker G, Kupferminc M . Pre-eclampsia. Lancet. 2005; 365(9461):785-99. DOI: 10.1016/S0140-6736(05)17987-2. View

11.

Afroze S, Kalagiri R, Reyes M, Zimmerman J, Beeram M, Drever N . Apoptotic and stress signaling markers are augmented in preeclamptic placenta and umbilical cord. BBA Clin. 2016; 6:25-30. PMC: 4906135. DOI: 10.1016/j.bbacli.2016.05.003. View

12.

Young B, Levine R, Karumanchi S . Pathogenesis of preeclampsia. Annu Rev Pathol. 2010; 5:173-92. DOI: 10.1146/annurev-pathol-121808-102149. View

13.

Tal R . The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod. 2012; 87(6):134. DOI: 10.1095/biolreprod.112.102723. View

14.

Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl M . An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2009; 202(2):161.e1-161.e11. DOI: 10.1016/j.ajog.2009.09.016. View

15.

Li D, Sorensen L, Brooke B, Urness L, Davis E, Taylor D . Defective angiogenesis in mice lacking endoglin. Science. 1999; 284(5419):1534-7. DOI: 10.1126/science.284.5419.1534. View

16.

Das U . Cytokines, angiogenic, and antiangiogenic factors and bioactive lipids in preeclampsia. Nutrition. 2015; 31(9):1083-95. DOI: 10.1016/j.nut.2015.03.013. View

17.

Redman C, Sargent I . Pre-eclampsia, the placenta and the maternal systemic inflammatory response--a review. Placenta. 2003; 24 Suppl A:S21-7. DOI: 10.1053/plac.2002.0930. View

18.

Kendall R, Wang G, Thomas K . Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996; 226(2):324-8. DOI: 10.1006/bbrc.1996.1355. View

19.

LaMarca B, Brewer J, Wallace K . IL-6-induced pathophysiology during pre-eclampsia: potential therapeutic role for magnesium sulfate?. Int J Interferon Cytokine Mediat Res. 2011; 2011(3):59-64. PMC: 3227031. DOI: 10.2147/IJICMR.S16320. View

20.

Roberts J, Taylor R, Musci T, Rodgers G, Hubel C, McLaughlin M . Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161(5):1200-4. DOI: 10.1016/0002-9378(89)90665-0. View